EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

TGF‐β‐activated kinase‐1 inhibitor LL‐Z1640‐2 reduces joint inflammation and bone destruction in mouse models of rheumatoid arthritis by inhibiting NLRP3 inflammasome, TACE, TNF‐α and RANKL expression

Hirofumi Tenshin, Jumpei Teramachi, Mohannad Ashtar, Masahiro Hiasa, Yusuke Inoue, Asuka Oda, Kotaro Tanimoto, So Shimizu, Yoshiki Higa, Takeshi Harada, Masahiro Oura, Kimiko Sogabe und 10 weitere

Clinical & Translational Immunology · 2022-01 · 11 (1)

DOI: 10.1002/cti2.1371 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical & Translational Immunology, online erschienen am 19.01.2022. Verfasst von Hirofumi Tenshin und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthodontics and Dentofacial Orthopedics Tokushima University Graduate School of Biomedical Sciences Tokushima Japan. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Aberrant NLRP3 inflammasome activation has been demonstrated in rheumatoid arthritis (RA), which may contribute to debilitating inflammation and bone destruction. Here, we explored the efficacy of the potent TGF‐β‐activated kinase‐1 (TAK1) inhibitor LL‐Z1640‐2 (LLZ) on joint inflammation and bone destruction in collagen‐induced arthritis (CIA).

Methods

LL‐Z1640‐2 was administered every other day in CIA mice. Clinical and histological evaluation was performed. Priming and activation of NLRP3 inflammasome and osteoclastogenic activity were assessed.

Results

NLRP3 inflammasome formation was observed in synovial macrophages and osteoclasts (OCs) in CIA mice. TACE and RANKL were also overexpressed in synovial macrophages and fibroblasts, respectively, in the CIA joints. Treatment with LLZ mitigated all the above changes. As a result, LLZ markedly suppressed synovial hypertrophy and pannus formation to alleviate pain and inflammation in CIA mice. LLZ could block the priming and activation of NLRP3 inflammasome in RAW264.7 macrophage cell line, primary bone marrow macrophages and OCs upon treatment with LPS followed by ATP, thereby suppressing their IL‐1β production. LLZ also suppressed LPS‐induced production of TACE and TNF‐α in bone marrow macrophages and abolished IL‐1β‐induced production of MMP‐3, IL‐6 and RANKL in synovial fibroblasts. In addition, LLZ directly inhibits RANKL‐mediated OC formation and activation.

Conclusion

TAK1 inhibition with LLZ may become a novel treatment strategy to effectively alleviate inflammasome‐mediated inflammation and RANKL‐induced osteoclastic bone destruction in joints alongside its potent suppression of TNF‐α and IL‐6 production and proteinase‐mediated pathological processes in RA.

Schlagwörter

Stichwörter der Autor:innen

LL‐Z1640‐2NLRP3 inflammasomeTAK1macrophageosteoclastrheumatoid arthritissynovial fibroblasts

Autor:innen und Institutionen

  • Department of Orthodontics and Dentofacial Orthopedics Tokushima University Graduate School of Biomedical Sciences Tokushima Japan.
  • Department of Hematology, Endocrinology and Metabolism Tokushima University Graduate School of Biomedical Sciences Tokushima Japan.
  • Department of Oral Function and Anatomy, Graduate School of Medicine Dentistry and Pharmaceutical Sciences Okayama University Okayama Japan.
  • Department of Nutrition and Metabolism Tokushima University Graduate School of Biomedical Sciences Tokushima Japan.
  • Department of Bioregulatory Sciences Tokushima University Graduate School of Biomedical Sciences Tokushima Japan.
  • Fujii Memorial Institute of Medical Sciences Tokushima University Tokushima Japan.

ORCID-Profile: Masahiro Abe

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Tenshin, H., Teramachi, J., Ashtar, M., Hiasa, M., Inoue, Y., Oda, A., Tanimoto, K., Shimizu, S., Higa, Y., Harada, T., Oura, M., Sogabe, K., Hara, T., Sumitani, R., Maruhashi, T., Sebe, M., Tsutsumi, R., Sakaue, H., Endo, I., …, & Abe, M. (2022). TGF‐β‐activated kinase‐1 inhibitor LL‐Z1640‐2 reduces joint inflammation and bone destruction in mouse models of rheumatoid arthritis by inhibiting NLRP3 inflammasome, TACE, TNF‐α and RANKL expression. Clinical & Translational Immunology, 11(1). https://doi.org/10.1002/cti2.1371

Vancouver

Tenshin H, Teramachi J, Ashtar M, Hiasa M, Inoue Y, Oda A, et al. TGF‐β‐activated kinase‐1 inhibitor LL‐Z1640‐2 reduces joint inflammation and bone destruction in mouse models of rheumatoid arthritis by inhibiting NLRP3 inflammasome, TACE, TNF‐α and RANKL expression. Clinical & Translational Immunology. 2022;11(1). doi:10.1002/cti2.1371

BibTeX
@article{Tenshin2022,
  author = {Tenshin, Hirofumi and Teramachi, Jumpei and Ashtar, Mohannad and Hiasa, Masahiro and Inoue, Yusuke and Oda, Asuka and Tanimoto, Kotaro and Shimizu, So and Higa, Yoshiki and Harada, Takeshi and Oura, Masahiro and Sogabe, Kimiko and Hara, Tomoyo and Sumitani, Ryohei and Maruhashi, Tomoko and Sebe, Mayu and Tsutsumi, Rie and Sakaue, Hiroshi and Endo, Itsuro and Matsumoto, Toshio and Tanaka, Eiji and Abe, Masahiro},
  title = {TGF‐β‐activated kinase‐1 inhibitor LL‐Z1640‐2 reduces joint inflammation and bone destruction in mouse models of rheumatoid arthritis by inhibiting NLRP3 inflammasome, TACE, TNF‐α and RANKL expression},
  journal = {Clinical & Translational Immunology},
  year = {2022},
  volume = {11},
  number = {1},
  doi = {10.1002/cti2.1371}
}
Kostenlos starten →